A Literature review on cholesterol medicine in Pakistan has been published. This article focuses on the efficacy of rosuvastatin in reducing LDL-C. It also discusses the lower tolerance to statin therapy with an alternate-day regimen. The alternate-day regimen may be similar to standard daily dosing. In addition, there is a lower threshold for triglyceride reduction than with the daily regimen.
Rosuvastatin reduces LDL-C
One study showed that rosuvastatin significantly reduced LDL-C levels in patients with mixed hyperlipidaemia. The drug (cholesterol kam karne ki dawa) also significantly reduced remnant LDL and small, dense LDL. This study was performed in patients with an elevated risk for CVD, a condition characterized by high LDL-C levels. However, it should be noted that statins do not necessarily reduce total cholesterol levels.
To determine the effectiveness of rosuvastatin in reducing LDL-C, a literature search was performed using the terms fenofibrate, rosuvastatin, and ABT-335. We used MEDLINE, BIOSIS, EBSCOhost, and OVID to perform our literature search. We screened all English-based articles and analyzed the references cited in these articles.
The results of the study showed that rosuvastatin significantly reduced LDL-C while increasing HDL-C levels in patients. The changes in triglyceride levels were similar for both drugs, although there was a statistical difference between the two treatments. High levels of HDL-C appear to provide protection against CVD and high levels of TG may be associated with increased risk for this condition.
Lower threshold for tolerance of statin therapy
A recent study suggests that cholesterol-lowering medications (tablets for high cholesterol) are more effective in people with a lower threshold for statin tolerance. A study by the Agha Khan University suggested that patients in Pakistan may need a lower dose to achieve their target LDL levels than those in the U.S. The study also concluded that patients with lower thresholds for statin tolerance may benefit from alternate-day dosing.
The National Lipid Association defines statin intolerance as the presence of an adverse effect limiting the patient's quality of life and requiring reduction in the medication. A similar definition by the International Lipid Expert Panel (ILEP) showed a 6.7% prevalence rate for statin intolerance. Nevertheless, the European Atherosclerosis Society uses a stricter definition, focusing on statin-associated muscle symptoms, elevations in creatinine kinase levels, and temporal association between discontinuation of statin therapy and symptoms.
Post a Comment